Twice as NICE: CAR-T therapies recommended for treatment of aggressive blood cancer

In final draft guidance, the National Institute for Health and Care Excellence (NICE) recommended two new personalized CAR-T therapies for use within the Cancer Drugs Fund (CDF). The treatments are set to benefit approximately 600 people in England, with aggressive forms of blood cancer, per year. The treatment options both come from Kite Pharma (CA, USA), a company who have existed at the forefront of CAR-T immunotherapy for over a decade. Yescarta® (axicabtagene ciloleucel) has been recommended as a CAR-T therapy for adult patients with diffuse large-B-cell lymphoma, an aggressive cancer that propagates in the lymphatic system. Although this drug...